{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T22:15:25Z","timestamp":1761948925516,"version":"build-2065373602"},"reference-count":22,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2025,9,25]],"date-time":"2025-09-25T00:00:00Z","timestamp":1758758400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2025,9,25]],"date-time":"2025-09-25T00:00:00Z","timestamp":1758758400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"name":"Bayer U.S. LLC"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Diabetes Ther"],"published-print":{"date-parts":[[2025,11]]},"DOI":"10.1007\/s13300-025-01787-8","type":"journal-article","created":{"date-parts":[[2025,9,25]],"date-time":"2025-09-25T06:59:24Z","timestamp":1758783564000},"page":"2257-2264","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Risk of Progression and Costs of Care for Patients with Type 2 Diabetes and Chronic Kidney Disease"],"prefix":"10.1007","volume":"16","author":[{"given":"Navdeep","family":"Tangri","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rakesh","family":"Singh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Keith A.","family":"Betts","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuxian","family":"Du","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sophie","family":"Gao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Arvind","family":"Katta","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Youssef M. K.","family":"Farag","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Samuel T.","family":"Fatoba","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hongjiao","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jingyi","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thomas","family":"Ferguson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Reid","family":"Whitlock","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Silvia J.","family":"Leon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ajay K.","family":"Singh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,9,25]]},"reference":[{"issue":"3","key":"1787_CR1","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1016\/j.ecl.2021.05.001","volume":"50","author":"J Pearson-Stuttard","year":"2021","unstructured":"Pearson-Stuttard J, Buckley J, Cicek M, et al. The changing nature of mortality and morbidity in patients with diabetes. Endocrinol Metab Clin North Am. 2021;50(3):357\u201368.","journal-title":"Endocrinol Metab Clin North Am"},{"issue":"12","key":"1787_CR2","first-page":"1506","volume":"26","author":"K Folkerts","year":"2020","unstructured":"Folkerts K, Petruski-Ivleva N, Kelly A, et al. Annual health care resource utilization and cost among type 2 diabetes patients with newly recognized chronic kidney disease within a large U.S. administrative claims database. J Manag Care Spec Pharm. 2020;26(12):1506\u201316.","journal-title":"J Manag Care Spec Pharm"},{"issue":"4","key":"1787_CR3","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1016\/j.kint.2023.10.018","volume":"105","author":"Kidney Disease: Improving Global Outcomes (KDIGO) CKD Work Group","year":"2024","unstructured":"Kidney Disease: Improving Global Outcomes (KDIGO) CKD Work Group. KDIGO 2024 clinical practice guideline for the evaluation and management of chronic kidney disease. Kidney Int. 2024;105(4):117\u2013314.","journal-title":"Kidney Int"},{"issue":"11","key":"1787_CR4","doi-asserted-by":"publisher","DOI":"10.1016\/j.xkme.2022.100532","volume":"4","author":"CD Mullins","year":"2022","unstructured":"Mullins CD, Pantalone KM, Betts KA, et al. CKD progression and economic burden in individuals with CKD associated with type 2 diabetes. Kidney Med. 2022;4(11): 100532.","journal-title":"Kidney Med"},{"issue":"6","key":"1787_CR5","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2021.12828","volume":"4","author":"P Liu","year":"2021","unstructured":"Liu P, Quinn RR, Lam NN, et al. Progression and regression of chronic kidney disease by age among adults in a population-based cohort in Alberta, Canada. JAMA Netw Open. 2021;4(6): e2112828.","journal-title":"JAMA Netw Open"},{"issue":"9","key":"1787_CR6","doi-asserted-by":"publisher","first-page":"2055","DOI":"10.2337\/dc22-0698","volume":"45","author":"ME Grams","year":"2022","unstructured":"Grams ME, Brunskill NJ, Ballew SH, et al. Development and validation of prediction models of adverse kidney outcomes in the population with and without diabetes. Diabetes Care. 2022;45(9):2055\u201363.","journal-title":"Diabetes Care"},{"issue":"8","key":"1787_CR7","doi-asserted-by":"publisher","first-page":"731","DOI":"10.34067\/KID.0002252020","volume":"1","author":"K Chauhan","year":"2020","unstructured":"Chauhan K, Nadkarni GN, Fleming F, et al. Initial validation of a machine learning-derived prognostic test (KidneyIntelX) integrating biomarkers and electronic health record data to predict longitudinal kidney outcomes. Kidney360. 2020;1(8):731\u20139.","journal-title":"Kidney360"},{"issue":"7","key":"1787_CR8","doi-asserted-by":"publisher","first-page":"1504","DOI":"10.1007\/s00125-021-05444-0","volume":"64","author":"L Chan","year":"2021","unstructured":"Chan L, Nadkarni GN, Fleming F, et al. Derivation and validation of a machine learning risk score using biomarker and electronic patient data to predict progression of diabetic kidney disease. Diabetologia. 2021;64(7):1504\u201315.","journal-title":"Diabetologia"},{"issue":"12","key":"1787_CR9","doi-asserted-by":"publisher","first-page":"3779","DOI":"10.1111\/dom.15273","volume":"25","author":"GN Nadkarni","year":"2023","unstructured":"Nadkarni GN, Stapleton S, Takale D, et al. Derivation and independent validation of kidneyintelX.dkd: a prognostic test for the assessment of diabetic kidney disease progression. Diabetes Obes Metab. 2023;25(12):3779\u201387.","journal-title":"Diabetes Obes Metab"},{"issue":"8","key":"1787_CR10","doi-asserted-by":"publisher","first-page":"1772","DOI":"10.1016\/j.ekir.2022.05.004","volume":"7","author":"T Ferguson","year":"2022","unstructured":"Ferguson T, Ravani P, Sood MM, et al. Development and external validation of a machine learning model for progression of CKD. Kidney Int Rep. 2022;7(8):1772\u201381.","journal-title":"Kidney Int Rep"},{"issue":"4","key":"1787_CR11","doi-asserted-by":"publisher","DOI":"10.1093\/ckj\/sfae052","volume":"17","author":"N Tangri","year":"2024","unstructured":"Tangri N, Ferguson T, Leon SJ, et al. Validation of the Klinrisk chronic kidney disease progression model in the FIDELITY population. Clin Kidney J. 2024;17(4): sfae052.","journal-title":"Clin Kidney J"},{"issue":"8","key":"1787_CR12","doi-asserted-by":"publisher","first-page":"3371","DOI":"10.1111\/dom.15678","volume":"26","author":"N Tangri","year":"2024","unstructured":"Tangri N, Ferguson TW, Bamforth RJ, et al. Machine learning for prediction of chronic kidney disease progression: validation of the Klinrisk model in the CANVAS program and CREDENCE trial. Diabetes Obes Metab. 2024;26(8):3371\u201380.","journal-title":"Diabetes Obes Metab"},{"issue":"15","key":"1787_CR13","doi-asserted-by":"publisher","first-page":"1553","DOI":"10.1001\/jama.2011.451","volume":"305","author":"N Tangri","year":"2011","unstructured":"Tangri N, Stevens LA, Griffith J, et al. A predictive model for progression of chronic kidney disease to kidney failure. JAMA. 2011;305(15):1553\u20139.","journal-title":"JAMA"},{"issue":"4","key":"1787_CR14","doi-asserted-by":"publisher","first-page":"514","DOI":"10.1053\/j.ajkd.2016.07.030","volume":"69","author":"N Tangri","year":"2017","unstructured":"Tangri N, Inker LA, Hiebert B, et al. A dynamic predictive model for progression of CKD. Am J Kidney Dis. 2017;69(4):514\u201320.","journal-title":"Am J Kidney Dis"},{"issue":"7","key":"1787_CR15","doi-asserted-by":"publisher","first-page":"1773","DOI":"10.1093\/ndt\/gft063","volume":"28","author":"MJ Peeters","year":"2013","unstructured":"Peeters MJ, van Zuilen AD, van den Brand JA, et al. Validation of the kidney failure risk equation in European CKD patients. Nephrol Dial Transplant. 2013;28(7):1773\u20139.","journal-title":"Nephrol Dial Transplant"},{"issue":"2","key":"1787_CR16","doi-asserted-by":"publisher","first-page":"174","DOI":"10.1001\/jamapediatrics.2017.4083","volume":"172","author":"E Winnicki","year":"2018","unstructured":"Winnicki E, McCulloch CE, Mitsnefes MM, et al. Use of the kidney failure risk equation to determine the risk of progression to end-stage renal disease in children with chronic kidney disease. JAMA Pediatr. 2018;172(2):174\u201380.","journal-title":"JAMA Pediatr"},{"issue":"2","key":"1787_CR17","doi-asserted-by":"publisher","first-page":"429","DOI":"10.1007\/s40620-023-01819-1","volume":"37","author":"E Gallego-Valcarce","year":"2024","unstructured":"Gallego-Valcarce E, Shabaka A, Tato-Ribera AM, et al. External validation of the KFRE and Grams prediction models for kidney failure and death in a Spanish cohort of patients with advanced chronic kidney disease. J Nephrol. 2024;37(2):429\u201337.","journal-title":"J Nephrol"},{"key":"1787_CR18","doi-asserted-by":"publisher","first-page":"205435811772278","DOI":"10.1177\/2054358117722782","volume":"4","author":"J Hingwala","year":"2017","unstructured":"Hingwala J, Wojciechowski P, Hiebert B, et al. Risk-based triage for nephrology referrals using the kidney failure risk equation. Can J Kidney Health Dis. 2017;4:2054358117722782.","journal-title":"Can J Kidney Health Dis"},{"issue":"Suppl 6","key":"1787_CR19","doi-asserted-by":"publisher","first-page":"s117","DOI":"10.7861\/clinmedicine.16-6-s117","volume":"16","author":"MW Taal","year":"2016","unstructured":"Taal MW. Chronic kidney disease: towards a risk-based approach. Clin Med (Lond). 2016;16(Suppl 6):s117\u201320.","journal-title":"Clin Med (Lond)"},{"key":"1787_CR20","doi-asserted-by":"publisher","first-page":"205435811984161","DOI":"10.1177\/2054358119841611","volume":"6","author":"O Harasemiw","year":"2019","unstructured":"Harasemiw O, Drummond N, Singer A, et al. Integrating risk-based care for patients with chronic kidney disease in the community: study protocol for a cluster randomized trial. Can J Kidney Health Dis. 2019;6:2054358119841611.","journal-title":"Can J Kidney Health Dis"},{"issue":"Suppl 1(Suppl 1","key":"1787_CR21","first-page":"S13","volume":"45","author":"MM Hammond","year":"2022","unstructured":"Hammond MM, Everitt IK, Khan SS. New strategies and therapies for the prevention of heart failure in high-risk patients. Clin Cardiol. 2022;45(Suppl 1(Suppl 1)):S13\u201325.","journal-title":"Clin Cardiol"},{"issue":"5","key":"1787_CR22","doi-asserted-by":"publisher","first-page":"e288","DOI":"10.1016\/S2589-7500(23)00025-0","volume":"5","author":"IRI Alberto","year":"2023","unstructured":"Alberto IRI, Alberto NRI, Ghosh AK, et al. The impact of commercial health datasets on medical research and health-care algorithms. Lancet Digital Health. 2023;5(5):e288\u201394.","journal-title":"Lancet Digital Health"}],"container-title":["Diabetes Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13300-025-01787-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s13300-025-01787-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13300-025-01787-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T22:09:48Z","timestamp":1761948588000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s13300-025-01787-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,25]]},"references-count":22,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2025,11]]}},"alternative-id":["1787"],"URL":"https:\/\/doi.org\/10.1007\/s13300-025-01787-8","relation":{},"ISSN":["1869-6953","1869-6961"],"issn-type":[{"type":"print","value":"1869-6953"},{"type":"electronic","value":"1869-6961"}],"subject":[],"published":{"date-parts":[[2025,9,25]]},"assertion":[{"value":"12 May 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 August 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 September 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Navdeep Tangri has received grants, personal fees, and other from Tricida Inc.; grants and personal fees from Astra Zeneca Inc., Janssen, and Bayer; personal fees from Otsuka Inc., Boehringer Ingelheim\/Eli Lilly, and Roche; other from PulseData and Mesentech; personal fees and other from Renibus outside the submitted work. He is also the founder of Klinrisk (which develops models for CKD progression) and ClinPredict Inc. (which implements models for electronic health records), and serves as a scientific advisor to PulseData Inc. (which develops customized machine learning models for adverse outcomes in kidney disease). Keith A. Betts and Jingyi Chen are employees of Analysis Group, Inc., a company that provided paid consulting services to the study sponsor, Bayer U.S. LLC. Sophie Gao and Hongjiao Liu were employees of Analysis Group, Inc. during the conduct of this study. Sophie Gao is now an employee of Taketa Inc. Hongjiao Liu is now a research associate at the University of Cambridge. Rakesh Singh, Yuxian Du, Youssef M.K. Farag, and Samuel T. Fatoba were employees of Bayer U.S. LLC during the development of this study, and may own stock options. Rakesh Singh is now an employee of Eli Lilly and Company. Yuxian Du is now an employee of Johnson & Johnson. Youssef M.K. Farag is now an employee of Alexion AstraZeneca Rare Disease Unit. Samuel T. Fatoba is now an employee of BioMarin Pharmaceutical Inc. Arvind Katta is an employee of Bayer U.S. LLC and may own stock options. Thomas Ferguson has received consulting fees from Klinrisk Inc., Strategic Health Resources, Quanta Dialysis Technologies Ltd., ClinPredict Ltd., and Guidepoint Global LLC, outside the submitted work, participates in the advisory board to the Loin Pain Hematuria study, and owns stock from Klinrisk Inc. Ajay K. Singh has received grants from the Centers for Disease Control and Prevention; consulting fees from Bayer, GSK, Zydus, Nephrology Times, and Chinook; and he is now an employee of Alexion AstraZeneca Rare Disease Unit. Reid Whitlock and Silvia J. Leon have no conflicts of interest to disclose.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"The authors received permission from Optum to access their database. This study was considered exempt research under 45 CFR \u00a7 46.104(d)(4) as it involved only the secondary use of data that were de-identified in compliance with the Health Insurance Portability and Accountability Act (HIPAA), specifically, 45 CFR \u00a7 164.514.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}}]}}